Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

BMC Cancer

Table 3 Concomitant BRAF mutations with KRAS or NRAS mutations in the MAPK pathway

Kinase activity	Diagnosis^a	BRAF ^b	RAS ^c
Activated
Case P1	Melanoma (71–90 %)	G466A^d (30 %)	KRAS/G12D (49 %)
Case P2	colorectal cancer (41–60 %)	V600E (29 %)	KRAS/G15S (8.4 %)
Case P3	Melanoma (61–80 %)	K601E (35 %)	NRAS/G13N (34 %)
Impaired
Case P4	Colorectal cancer (71–90 %)	Y472C (40 %)	KRAS/G12V (40 %)
Case P5	Colorectal cancer (51–70 %)	D594G (31 %)	KRAS/A59E (30 %)
Case P6	Lung cancer (51–70 %)	D594N (5.7 %)	KRAS/Q61H (24 %)
Unknown
Case P7	Lung cancer (41–60 %)	T440I (13 %)	KRAS/G12V (16 %)
Case P8^e	Melanoma (61–80 %)	S467L (26 %)	NRAS/Q61K (24 %)
Case P9	Lung cancer (21–40 %)	G469R (11 %)	KRAS/G12R (12 %)
Case P10	Lung cancer (41–60 %)	G469V (20 %)	KRAS/G13D (25 %)

^aEstimated tumor cell percentage of the specimens was indicated in the parenthesis
^bNucleotide changes of BRAF mutations were shown in Table 2. Percentage in the parenthesis indicates mutant allele frequency
^cactivating KRAS or NRAS mutations except KRAS p.G15S (c.43G > A) of unknown significance. G12V: c.35G > T;; G12R: c.34G > C; G13D: c.38G > A; A59E: c.176C > A; Q61H: c.183A > C; Q61K: c.181C > A. Percentage in the parenthesis indicates mutant allele frequency
^dintermediate -activity mutant by Wan et al. [13]
^esame case as M8 with BRAF, NRAS and PIK3CA mutations in Table 4

ISSN: 1471-2407